Article

Radiotherapy for subfoveal CNV has early, but not durable benefits

Author(s):

Fort Lauderdale, FL-High-dose (5 3 4-Gy fractions; 6 MeV) external-beam radiation therapy has only a modest and very short-lived benefit in the treatment of subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD), according to an interim analysis of data from the Age-Related Macular Degeneration Radiotherapy Trial (AMDRT).

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Cranial nerve six palsy with chemosis is a critical clue to cavernous carotid fistula
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
(Image credit: Ophthalmology Times) World Cornea Congress IX: Epi-on and accelerated crosslinking with Kenneth Beckman, MD
(Image credit: Ophthalmology Times) The synergy of cornea, cataract, and refractive surgery through the decades: insights from George O. Waring IV, MD
(Image credit: Ophthalmology Times) AGS 2025: A look at Gemini and the MIGS revolution with Mona Kaleem, MD
(Image credit: Ophthalmology Times) AGS 2025: Development and evaluation of an AI model to set target IOP with Jithin Yohannan, MD, MPH
© 2025 MJH Life Sciences

All rights reserved.